In fact, those breast cancer patients who develop NAFLD on anti-estrogen have better disease free survival and overall survival compared to those without NAFLD, suggesting that this type of drug-induced NAFLD is strongly correlated to target engagement by anti-estrogen on ERα 24. The gene discussed is ESR1; the disease is breast carcinoma.